Trial Profile
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Fludeoxyglucose F-18 (Primary) ; Flutemetamol-F-18 (Primary)
- Indications Chemotherapy-induced damage; Cognition disorders
- Focus Diagnostic use; Proof of concept
- 18 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2026.
- 03 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2025.